Treatment Response Prediction of Nasopharyngeal Carcinoma Based on Histogram Analysis of Diffusional Kurtosis Imaging

REFERENCES

1. 1.↵
   2. Chua ML,
   3. Wee JT,
   4. Hui EP, et al

   . Nasopharyngeal carcinoma. Lancet 2016;387:1012–24 doi:10.1016/S0140-6736(15)00055-0 pmid:26321262

   CrossRefPubMed
2. 2.↵
   2. Yang H,
   3. Chen X,
   4. Lin S, et al

   . Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a prospective, multi-center, randomized clinical trial. Radiother Oncol 2018;126:37–42 doi:10.1016/j.radonc.2017.07.020 pmid:28864073

   CrossRefPubMed
3. 3.↵
   2. Cao SM,
   3. Yang Q,
   4. Guo L, et al

   . Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer 2017;75:14–23 doi:10.1016/j.ejca.2016.12.039 pmid:28214653

   CrossRefPubMed
4. 4.↵
   2. Yao JJ,
   3. Zhang LL,
   4. Gao TS, et al

   . Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Biol Ther 2018:1–6. [Epub ahead of print] doi:10.1080/15384047.2018.1491501 pmid:30081714

   CrossRefPubMed
5. 5.↵
   2. Zheng D,
   3. Chen Y,
   4. Liu X, et al

   . Early response to chemoradiation therapy for nasopharyngeal carcinoma treatment: value of dynamic contrast-enhanced 3.0 T MRI. J Magn Reson Imaging 2015;41:1528–40 doi:10.1002/jmri.24723 pmid:25136770

   CrossRefPubMed
6. 6.↵
   2. Zheng D,
   3. Lai G,
   4. Chen Y, et al

   . Integrating dynamic contrast-enhanced magnetic resonance imaging and diffusion kurtosis imaging for neoadjuvant chemotherapy assessment of nasopharyngeal carcinoma. J Magn Reson Imaging 2018;48:1208–16 doi:10.1002/jmri.26164 pmid:29693765

   CrossRefPubMed
7. 7.↵
   2. Ai QY,
   3. King AD,
   4. Law BK, et al

   . Diffusion-weighted imaging of nasopharyngeal carcinoma to predict distant metastases. Eur Arch Otorhinolaryngol 2017;274:1045–51 doi:10.1007/s00405-016-4333-6 pmid:27722898

   CrossRefPubMed
8. 8.↵
   2. Zhang Y,
   3. Liu X,
   4. Zhang Y, et al

   . Prognostic value of the primary lesion apparent diffusion coefficient (ADC) in nasopharyngeal carcinoma: a retrospective study of 541 cases. Sci Rep 2015;5:12242 doi:10.1038/srep12242 pmid:26184509

   CrossRefPubMed
9. 9.↵
   2. Jensen JH,
   3. Helpern JA,
   4. Ramani A, et al

   . Diffusional kurtosis imaging: the quantification of non-Gaussian water diffusion by means of magnetic resonance imaging. Magn Reson Med 2005;53:1432–40 doi:10.1002/mrm.20508 pmid:15906300

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Sun K,
    3. Chen X,
    4. Chai W, et al

    . Breast cancer: diffusion kurtosis MR imaging: diagnostic accuracy and correlation with clinical-pathologic factors. Radiology 2015;277:46–55 doi:10.1148/radiol.15141625 pmid:25938679

    CrossRefPubMed
11. 11.↵
    2. Xu XQ,
    3. Ma G,
    4. Wang YJ, et al

    . Histogram analysis of diffusion kurtosis imaging of nasopharyngeal carcinoma: correlation between quantitative parameters and clinical stage. Oncotarget 2017;8:47230–38 doi:10.18632/oncotarget.17591 pmid:28525383

    CrossRefPubMed
12. 12.↵
    2. Fujima N,
    3. Yoshida D,
    4. Sakashita T, et al

    . Prediction of the treatment outcome using intravoxel incoherent motion and diffusional kurtosis imaging in nasal or sinonasal squamous cell carcinoma patients. Eur Radiol 2017;27:956–65 doi:10.1007/s00330-016-4440-1 pmid:27255401

    CrossRefPubMed
13. 13.↵
    2. Kang M,
    3. Zhou P,
    4. Li G, et al

    . Validation of the 8th edition of the UICC/AJCC staging system for nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. Oncotarget 2017;8:70586–94 doi:10.18632/oncotarget.19829 pmid:29050304

    CrossRefPubMed
14. 14.↵
    2. Jensen JH,
    3. Helpern JA

    . MRI quantification of non-Gaussian water diffusion by kurtosis analysis. NMR Biomed 2010;23:698–710 doi:10.1002/nbm.1518 pmid:20632416

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Just N

    . Improving tumour heterogeneity MRI assessment with histograms. Br J Cancer 2014;111:2205–13 doi:10.1038/bjc.2014.512 pmid:25268373

    CrossRefPubMed
16. 16.↵
    2. Eisenhauer EA,
    3. Therasse P,
    4. Bogaerts J, et al

    . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47 doi:10.1016/j.ejca.2008.10.026 pmid:19097774

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Fangzheng W,
    3. Chuner J,
    4. Lei W, et al

    . Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma. Oncotarget 2017;8:91150–61 doi:10.18632/oncotarget.20017 pmid:29207632

    CrossRefPubMed
18. 18.↵
    2. Peng H,
    3. Tang LL,
    4. Chen BB, et al

    . Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal carcinoma: a big-data intelligence platform-based analysis. Oral Oncol 2018;79:40–46 doi:10.1016/j.oraloncology.2018.02.011 pmid:29598949

    CrossRefPubMed
19. 19.↵
    2. Sun Y,
    3. Li WF,
    4. Chen NY, et al

    . Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016;17:1509–20 doi:10.1016/S1470-2045(16)30410-7 pmid:27686945

    CrossRefPubMed
20. 20.↵
    2. Jin T,
    3. Zhang Q,
    4. Jiang F, et al

    . Neoadjuvant chemotherapy with different dose regimens of docetaxel, cisplatin and fluorouracil (TPF) for locoregionally advanced nasopharyngeal carcinoma: a retrospective study. Oncotarget 2017;8:100764–72 doi:10.18632/oncotarget.21992 pmid:29246020

    CrossRefPubMed
21. 21.↵
    2. Lee NY,
    3. Zhang Q,
    4. Pfister DG, et al

    . Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol 2012;13:172–80 doi:10.1016/S1470-2045(11)70303-5 pmid:22178121

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Wang F,
    3. Jiang C,
    4. Ye Z, et al

    . Treatment outcomes of 257 patients with locoregionally advanced nasopharyngeal carcinoma treated with nimotuzumab plus intensity-modulated radiotherapy with or without chemotherapy: a single-institution experience. Transl Oncol 2018;11:65–73 doi:10.1016/j.tranon.2017.11.002 pmid:29202278

    CrossRefPubMed
23. 23.↵
    2. Zhong YH,
    3. Dai J,
    4. Wang XY, et al

    . Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma. Cancer Chemother Pharmacol 2013;71:1577–83 doi:10.1007/s00280-013-2157-2 pmid:23549883

    CrossRefPubMed
24. 24.↵
    2. Zhang L,
    3. Shan GP,
    4. Li P, et al

    . The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma. Med Oncol 2015;32:41 doi:10.1007/s12032-015-0505-2 pmid:25631634

    CrossRefPubMed
25. 25.↵
    2. Law BK,
    3. King AD,
    4. Bhatia KS

    . Diffusion-weighted imaging of nasopharyngeal carcinoma: can pretreatment DWI predict local failure based on long-term outcome? AJNR Am J Neuroradiol 2016;37:1706–12 doi:10.3174/ajnr.A4792 pmid:27151750

    Abstract/FREE Full Text
26. 26.
    2. Blazic IM,
    3. Lilic GB,
    4. Gajic MM

    . Quantitative assessment of rectal cancer response to neoadjuvant combined chemotherapy and radiation therapy: comparison of three methods of positioning region of interest for ADC measurements at diffusion-weighted MR imaging. Radiology 2017;282:615 doi:10.1148/radiol.2017164040 pmid:28099105

    CrossRefPubMed
27. 27.↵
    2. Chen Y,
    3. Ren W,
    4. Zheng D, et al

    . Diffusion kurtosis imaging predicts neoadjuvant chemotherapy responses within 4 days in advanced nasopharyngeal carcinoma patients. J Magn Reson Imaging 2015;42:1354–61 doi:10.1002/jmri.24910 pmid:25873208

    CrossRefPubMed
28. 28.↵
    2. Yan DF,
    3. Zhang WB,
    4. Ke SB, et al

    . The prognostic value of pretreatment tumor apparent diffusion coefficient values in nasopharyngeal carcinoma. BMC Cancer 2017;17:678 doi:10.1186/s12885-017-3658-x pmid:29020937

    CrossRefPubMed
29. 29.↵
    2. Jansen JF,
    3. Parra C,
    4. Lu Y, et al

    . Evaluation of head and neck tumors with functional MR imaging. Magn Reson Imaging Clin N Am 2016;24:123–33 doi:10.1016/j.mric.2015.08.011 pmid:26613878

    CrossRefPubMed
30. 30.↵
    2. Vandecaveye V,
    3. Dirix P,
    4. De Keyzer F, et al

    . Diffusion-weighted magnetic resonance imaging early after chemoradiotherapy to monitor treatment response in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2012;82:1098–107 doi:10.1016/j.ijrobp.2011.02.044 pmid:21514067

    CrossRefPubMed
31. 31.↵
    2. Zhang GY,
    3. Wang YJ,
    4. Liu JP, et al

    . Pretreatment diffusion-weighted MRI can predict the response to neoadjuvant chemotherapy in patients with nasopharyngeal carcinoma. Biomed Res Int 2015;2015:307943 doi:10.1155/2015/307943 pmid:26413513

    CrossRefPubMed
32. 32.↵
    2. Ryoo I,
    3. Kim JH,
    4. Choi SH, et al

    . Squamous cell carcinoma of the head and neck: comparison of diffusion-weighted MRI at b-values of 1,000 and 2,000 s/mm(2) to predict response to induction chemotherapy. Magn Reson Med Sci 2015;14:337–45 doi:10.2463/mrms.2015-0003 pmid:26104081

    CrossRefPubMed
33. 33.↵
    2. Obenauf AC,
    3. Zou Y,
    4. Ji AL, et al

    . Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 2015;520:368–72 doi:10.1038/nature14336 pmid:25807485

    CrossRefPubMed
34. 34.↵
    2. Raab P,
    3. Hattingen E,
    4. Franz K, et al

    . Cerebral gliomas: diffusional kurtosis imaging analysis of microstructural differences. Radiology 2010;254:876–81 doi:10.1148/radiol.09090819 pmid:20089718

    CrossRefPubMedWeb of Science
35. 35.↵
    2. Wang X,
    3. Tu N,
    4. Qin T, et al

    . Diffusion kurtosis imaging combined with DWI at 3-T MRI for detection and assessment of aggressiveness of prostate cancer. AJR Am J Roentgenol 2018;211:797–804 doi:10.2214/AJR.17.19249 pmid:30085835

    CrossRefPubMed
36. 36.↵
    2. Tamada T,
    3. Prabhu V,
    4. Li J, et al

    . Prostate cancer: diffusion-weighted MR imaging for detection and assessment of aggressiveness: comparison between conventional and kurtosis models. Radiology 2017;284:100–08 doi:10.1148/radiol.2017162321 pmid:28394755

    CrossRefPubMed
37. 37.↵
    2. Peeters F,
    3. Rommel D,
    4. Abarca-Quinones J, et al

    . Early (72-hour) detection of radiotherapy-induced changes in an experimental tumor model using diffusion-weighted imaging, diffusion tensor imaging, and Q-space imaging parameters: a comparative study. J Magn Reson Imaging 2012;35:409–17 doi:10.1002/jmri.22836 pmid:21990132

    CrossRefPubMed
38. 38.↵
    2. Beaulieu C

    . The basis of anisotropic water diffusion in the nervous system: a technical review. NMR Biomed 2002;15:435–55 doi:10.1002/nbm.782 pmid:12489094

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Xiao Y,
    3. Pan J,
    4. Chen Y, et al

    . Intravoxel incoherent motion-magnetic resonance imaging as an early predictor of treatment response to neoadjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Medicine (Baltimore) 2015;94:e973 doi:10.1097/MD.0000000000000973 pmid:26091468

    CrossRefPubMed
40. 40.↵
    2. Kuang F,
    3. Yan Z,
    4. Wang J, et al

    . The value of diffusion-weighted MRI to evaluate the response to radiochemotherapy for cervical cancer. Magn Reson Imaging 2014;32:342–49 doi:10.1016/j.mri.2013.12.007 pmid:24512795

    CrossRefPubMed
41. 41.↵
    2. Roethke MC,
    3. Kuder TA,
    4. Kuru TH, et al

    . Evaluation of diffusion kurtosis imaging versus standard diffusion imaging for detection and grading of peripheral zone prostate cancer. Invest Radiol 2015;50:483–89 doi:10.1097/RLI.0000000000000155 pmid:25867657

    CrossRefPubMed